We found that shRNA knockdown of RON in pancreatic cancer cell lines leads to up regulation in expression and activation of c-Met, suggesting the need to co-target or to use an agent that inhibits both of these kinases [44]. This evidence concerns the gene MET and pancreatic neoplasm.